Brightspring Health Services Inc

Brightspring Health Services Inc(BTSG)股票分析

$60.110

-0.739 (-1.23%)收盘时

Loading chart…
最高
61.000
开盘
60.760
成交量加权均价
60.29
成交量
1.81M
市值
—
最低
59.770
成交额
109.32M
企业价值/息税折旧摊销前利润(TTM)
18.55

BrightSpring Health Services, Inc. provides complementary home and community-based pharmacy and provides health solutions for complex populations in need of specialized and/or chronic care. Through the Company's service lines, including pharmacy, home health care and rehab care, it provides comprehensive and more integrated care and clinical solutions in all 50 states to customers, clients and patients. Its services are organized and managed through two reportable segments: Pharmacy Solutions and Provider Services. The Pharmacy Solutions segment operates long-term institutional pharmacies, hospice pharmacies, specialty oncology pharmacies, and home infusion centers. It provides infused, injectable, and oral medication services in the home and clinic. The Provider Services segment provides a variety of services to help manage the whole-person health of its patients in their homes and communities through services such as home health care and hospice care and long-term specialty care.

AI 分析 of Brightspring Health Services Inc (BTSG)

持有

Brightspring Health Services Inc (BTSG) is currently priced at $60.87, which is below several analyst price targets, including $70 from Deutsche Bank and $80 from KeyBanc. However, the stock has a low RSI of 39.53, indicating potential oversold conditions, but it also experienced a significant 4.5% drop over the last five days. The company has shown strong revenue growth, with a 58.52% year-to-date increase, but concerns about its free cash flow margin averaging only 1.3% could limit its ability to return capital to shareholders. Given these factors, it may be prudent to hold rather than buy at this time, especially considering the recent volatility in the stock price.

估值指标

Brightspring Health Services Inc(BTSG)当前预期市盈率为 22.17,5 年平均预期市盈率为 27.08。

预期市盈率

合理
5 年均值 P/E
27.08
当前P/E
22.17
高估
35.38
低估
18.78

预期 EV/EBITDA

高估
5 年均值 EV/EBITDA
12.95
当前EV/EBITDA
18.55
高估
17.06
低估
8.84

预期市销率

高估
5 年均值 P/S
0.38
当前P/S
0.69
高估
0.57
低估
0.19

Alphio AI 对 BTSG 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

乐

乐观

乐观 · 25%BTSG

$28.42

情景价格

基

基准

基准 · 50%BTSG

$25.10

情景价格

悲

悲观

悲观 · 25%BTSG

$20.54

情景价格

持有 BTSG 的大户

B

Braidwell LP

+ 持有BTSG

+24.47%

3个月收益率

O

Oak Ridge Investments, LLC

+ 持有BTSG

+7.95%

3个月收益率

C

CastleArk Management LLC

+ 持有BTSG

+4.66%

3个月收益率

F

Farallon Capital Management, L.L.C.

+ 持有BTSG

+1.94%

3个月收益率

I

Infrastructure Capital Advisors, LLC

+ 持有BTSG

+1.80%

3个月收益率

B

Blackstone Alternative Investment Advisors LLC

+ 持有BTSG

+0.03%

3个月收益率

BTSG 常见问题 —— 由 Alphio AI 解答

BrightSpring Health Services, Inc. provides complementary home and community-based pharmacy and provides health solutions for complex populations in need of specialized and/or chronic care. Through the Company's service lines, including pharmacy, home health care and rehab care, it provides comprehensive and more integrated care and clinical solutions in all 50 states to customers, clients and patients. Its services are organized and managed through two reportable segments: Pharmacy Solutions and Provider Services. The Pharmacy Solutions segment operates long-term institutional pharmacies, hospice pharmacies, specialty oncology pharmacies, and home infusion centers. It provides infused, injectable, and oral medication services in the home and clinic. The Provider Services segment provides a variety of services to help manage the whole-person health of its patients in their homes and communities through services such as home health care and hospice care and long-term specialty care. It operates in the Healthcare sector (HOME HEALTH CARE SERVICES industry).

Brightspring Health Services Inc (BTSG) is currently priced at $60.87, which is below several analyst price targets, including $70 from Deutsche Bank and $80 from KeyBanc. However, the stock has a low RSI of 39.53, indicating potential oversold conditions, but it also experienced a significant 4.5% drop over the last five days. The company has shown strong revenue growth, with a 58.52% year-to-date increase, but concerns about its free cash flow margin averaging only 1.3% could limit its ability to return capital to shareholders. Given these factors, it may be prudent to hold rather than buy at this time, especially considering the recent volatility in the stock price.

暂无帖子

注册或登录后参与讨论

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易